CVRx IncNASDAQ:CVRX
- LAST PRICE9.3200
- TODAY'S CHANGE (%)0.6000 (6.8807%)
- Bid / Lots9.0100/ 1
- Ask / Lots9.7400/ 1
- Open / Previous Close8.7100 / 8.7200
- Day Range
- 52 Week Range
- Volume173,334
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CVRX |
|---|---|---|
| 09:32 ET | 506 | 8.71 |
| 09:34 ET | 100 | 8.82 |
| 09:45 ET | 400 | 8.81 |
| 09:56 ET | 100 | 8.9 |
| 09:59 ET | 500 | 8.81 |
| 10:15 ET | 100 | 8.825 |
| 10:19 ET | 1100 | 8.86 |
| 10:24 ET | 643 | 8.88 |
| 10:26 ET | 1700 | 8.88 |
| 10:28 ET | 100 | 8.88 |
| 10:30 ET | 749 | 8.88 |
| 10:32 ET | 353 | 8.88 |
| 10:33 ET | 355 | 8.88 |
| 10:35 ET | 154 | 8.88 |
| 10:42 ET | 100 | 8.955 |
| 10:44 ET | 700 | 8.89 |
| 10:50 ET | 1107 | 8.89 |
| 10:55 ET | 136 | 8.87 |
| 10:57 ET | 300 | 8.88 |
| 11:00 ET | 770 | 8.86 |
| 11:04 ET | 100 | 8.88 |
| 11:06 ET | 600 | 8.88 |
| 11:09 ET | 3651 | 8.95 |
| 11:13 ET | 100 | 8.95 |
| 11:18 ET | 3811 | 9.0617 |
| 11:20 ET | 400 | 9.09 |
| 11:27 ET | 100 | 9.155 |
| 11:33 ET | 3119 | 9.14 |
| 11:36 ET | 361 | 9.15 |
| 11:42 ET | 2000 | 9.15 |
| 11:44 ET | 200 | 9.16 |
| 11:47 ET | 2861 | 9.19 |
| 11:49 ET | 2421 | 9.21 |
| 12:03 ET | 2783 | 9.365 |
| 12:05 ET | 200 | 9.35 |
| 12:09 ET | 1499 | 9.29 |
| 12:12 ET | 1200 | 9.26 |
| 12:16 ET | 3700 | 9.14 |
| 12:20 ET | 1400 | 9.1 |
| 12:23 ET | 322 | 9.11 |
| 12:25 ET | 400 | 9.11 |
| 12:27 ET | 600 | 9.09 |
| 12:30 ET | 200 | 9.1193 |
| 12:32 ET | 400 | 9.09 |
| 12:38 ET | 223 | 9.03 |
| 12:39 ET | 2100 | 9 |
| 12:43 ET | 600 | 9.02 |
| 12:48 ET | 3700 | 9.11 |
| 12:56 ET | 100 | 9.13 |
| 12:59 ET | 11301 | 9.2 |
| 01:01 ET | 200 | 9.2 |
| 01:03 ET | 1100 | 9.2 |
| 01:06 ET | 500 | 9.17 |
| 01:10 ET | 2025 | 9.2 |
| 01:19 ET | 100 | 9.17 |
| 01:21 ET | 4568 | 9.2 |
| 01:28 ET | 700 | 9.175 |
| 01:33 ET | 200 | 9.18 |
| 01:35 ET | 100 | 9.17 |
| 01:39 ET | 100 | 9.18 |
| 01:42 ET | 900 | 9.15 |
| 01:44 ET | 299 | 9.1301 |
| 01:46 ET | 100 | 9.15 |
| 01:48 ET | 100 | 9.15 |
| 01:51 ET | 200 | 9.16 |
| 01:53 ET | 1369 | 9.25 |
| 01:55 ET | 100 | 9.245 |
| 02:00 ET | 749 | 9.2769 |
| 02:04 ET | 2581 | 9.29 |
| 02:06 ET | 100 | 9.2666 |
| 02:08 ET | 7780 | 9.4 |
| 02:09 ET | 1600 | 9.355 |
| 02:15 ET | 1300 | 9.355 |
| 02:20 ET | 100 | 9.375 |
| 02:24 ET | 700 | 9.3 |
| 02:27 ET | 300 | 9.33 |
| 02:29 ET | 1000 | 9.3 |
| 02:36 ET | 200 | 9.335 |
| 02:38 ET | 200 | 9.32 |
| 02:44 ET | 1050 | 9.3591 |
| 02:45 ET | 1300 | 9.26 |
| 02:47 ET | 1500 | 9.31 |
| 02:49 ET | 100 | 9.31 |
| 02:51 ET | 1590 | 9.31 |
| 02:54 ET | 1270 | 9.34 |
| 02:56 ET | 100 | 9.335 |
| 03:02 ET | 499 | 9.36 |
| 03:05 ET | 400 | 9.405 |
| 03:07 ET | 200 | 9.35 |
| 03:09 ET | 100 | 9.4 |
| 03:12 ET | 217 | 9.4 |
| 03:14 ET | 200 | 9.38 |
| 03:18 ET | 100 | 9.4 |
| 03:20 ET | 513 | 9.37 |
| 03:21 ET | 651 | 9.38 |
| 03:23 ET | 400 | 9.37 |
| 03:25 ET | 667 | 9.37 |
| 03:27 ET | 800 | 9.412 |
| 03:32 ET | 2667 | 9.38 |
| 03:34 ET | 1952 | 9.31 |
| 03:36 ET | 1188 | 9.325 |
| 03:38 ET | 300 | 9.33 |
| 03:39 ET | 1600 | 9.32 |
| 03:41 ET | 938 | 9.305 |
| 03:43 ET | 6312 | 9.31 |
| 03:45 ET | 1549 | 9.35 |
| 03:48 ET | 504 | 9.3276 |
| 03:50 ET | 1533 | 9.34 |
| 03:52 ET | 607 | 9.38 |
| 03:54 ET | 3188 | 9.39 |
| 03:56 ET | 1710 | 9.43 |
| 03:57 ET | 4105 | 9.37 |
| 03:59 ET | 1836 | 9.32 |
Mar 21, 2023
BRIEF-Totality Of Evidence From Beat-Hf Study Shows Cvrx’S Barostim Provides Long-Term Benefits For Patients With Heart Failure, from 11:14AM ET on Tuesday Mar 21, 2023 by Thomson Reuters
11:14AM ET on Tuesday Mar 21, 2023 by Thomson ReutersTotality of Evidence from BeAT-HF Study Shows CVRx's Barostim Provides Long-term Benefits for Patients with Heart Failure, from 11:02AM ET on Tuesday Mar 21, 2023 by GlobeNewswire
11:02AM ET on Tuesday Mar 21, 2023 by GlobeNewswire
Mar 20, 2023
Top Premarket Decliners, from 7:48AM ET on Monday Mar 20, 2023 by MT Newswires
7:48AM ET on Monday Mar 20, 2023 by MT Newswires
Mar 16, 2023
BRIEF-Cvrx Reiterates Plans To Discuss The Preliminary Results From The Post-Market Phase Of The Beat-Hf Trial At Tht 2023 And Schedules A Conference Call, from 9:14AM ET on Thursday Mar 16, 2023 by Thomson Reuters
9:14AM ET on Thursday Mar 16, 2023 by Thomson ReutersCVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call, from 8:30AM ET on Thursday Mar 16, 2023 by GlobeNewswire
8:30AM ET on Thursday Mar 16, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CVRx Inc | 180.4M | -4.6x | --- |
KORU Medical Systems Inc | 191.0M | -21.9x | --- |
Perspective Therapeutics Inc | 170.0M | -8.7x | --- |
Semler Scientific Inc | 176.2M | 14.9x | --- |
Beyond Air Inc | 197.0M | -3.6x | --- |
Asensus Surgical Inc | 149.1M | -2.1x | --- |
Company Information
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
Contact Information
- Headquarters
- 9201 West Broadway Avenue, Suite 650MINNEAPOLIS, MN, United States 55445
- Phone
- 763-416-2850
- Fax
- 763-416-2841
Executives
- President, Chief Executive Officer, Director
- Nadim Yared
- Chief Financial Officer
- Jared Oasheim
- Chief Marketing Officer
- Paul Verrastro
- Vice President - US Sales
- Craig Palmer
- Vice President - Regulatory Affairs and Quality Assurance
- Dean Bruhn-Ding
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $180.4M |
|---|---|
Revenue (TTM) | $22.5M |
Shares Outstanding | 20.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.02 |
Book Value | $5.29 |
P/E Ratio | -4.6x |
Price/Sales (TTM) | 8.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -183.48% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
